Suppr超能文献

骨关节炎治疗的前景。

Prospects for Therapies in Osteoarthritis.

机构信息

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK.

Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Rd, Leeds, LS7 4SA, UK.

出版信息

Calcif Tissue Int. 2021 Sep;109(3):339-350. doi: 10.1007/s00223-020-00672-9. Epub 2020 Feb 13.

Abstract

Osteoarthritis (OA) is a chronic, debilitating disease affecting millions of people worldwide. Management of OA involves pharmacological and non-pharmacological approaches. Conventional pharmacological treatments have limited efficacy and are associated with a number of side-effects, restricting the number of patients who can use them. New pharmacological therapies for managing OA are required and a number have been developed targeting different tissues in OA: bone and cartilage, synovium and nerves. However, there has been overall limited success. Disease-modifying osteoarthritis drugs (DMOADs) are a putative class of therapies aimed at improving OA structural pathologies and consequent symptoms. Recent DMOAD studies have demonstrated some promising therapies but also provided new considerations for future trials.

摘要

骨关节炎(OA)是一种影响全球数百万人的慢性、使人虚弱的疾病。OA 的管理包括药物和非药物方法。传统的药物治疗效果有限,并且与许多副作用相关,限制了可以使用它们的患者数量。需要新的药物治疗方法来管理 OA,并且已经开发了许多针对 OA 不同组织的治疗方法:骨骼和软骨、滑膜和神经。然而,总体上成功有限。改善骨关节炎结构病理学和相应症状的潜在治疗方法。最近的 DMOAD 研究已经证明了一些有前途的治疗方法,但也为未来的试验提供了新的考虑因素。

相似文献

1
Prospects for Therapies in Osteoarthritis.骨关节炎治疗的前景。
Calcif Tissue Int. 2021 Sep;109(3):339-350. doi: 10.1007/s00223-020-00672-9. Epub 2020 Feb 13.
2
Update on novel pharmacological therapies for osteoarthritis.骨关节炎新型药物治疗进展
Ther Adv Musculoskelet Dis. 2019 Jul 23;11:1759720X19864492. doi: 10.1177/1759720X19864492. eCollection 2019.
3
Current Models for Development of Disease-Modifying Osteoarthritis Drugs.当前治疗骨关节炎的疾病修饰药物的开发模型。
Tissue Eng Part C Methods. 2021 Feb;27(2):124-138. doi: 10.1089/ten.TEC.2020.0309. Epub 2021 Feb 4.
5
New developments in osteoarthritis pharmacological therapies.骨关节炎药理学治疗的新进展。
Rheumatology (Oxford). 2021 Dec 24;60(Suppl 6):vi1-vi11. doi: 10.1093/rheumatology/keab679.
7
Dehydroepiandrosterone and Experimental Osteoarthritis.去氢表雄酮与实验性骨关节炎。
Vitam Horm. 2018;108:367-384. doi: 10.1016/bs.vh.2018.01.021. Epub 2018 Feb 19.
9
Prospects of Disease-Modifying Osteoarthritis Drugs.改善病情的骨关节炎药物的前景
Rheum Dis Clin North Am. 2024 Aug;50(3):483-518. doi: 10.1016/j.rdc.2024.03.003.
10
Prospects of Disease-Modifying Osteoarthritis Drugs.骨关节炎治疗药物的前景。
Clin Geriatr Med. 2022 May;38(2):397-432. doi: 10.1016/j.cger.2021.11.010.

引用本文的文献

5
Therapeutic Controlled Release Strategies for Human Osteoarthritis.人类骨关节炎的治疗性控释策略
Adv Healthc Mater. 2025 Jan;14(2):e2402737. doi: 10.1002/adhm.202402737. Epub 2024 Nov 6.
6
Glycolysis: an emerging regulator of osteoarthritis.糖酵解:骨关节炎的一个新调控因子。
Front Immunol. 2024 Jan 9;14:1327852. doi: 10.3389/fimmu.2023.1327852. eCollection 2023.
7
IL-17 in osteoarthritis: A narrative review.骨关节炎中的白细胞介素-17:一项叙述性综述。
Open Life Sci. 2023 Oct 14;18(1):20220747. doi: 10.1515/biol-2022-0747. eCollection 2023.
9
The Current Role of Disease-modifying Osteoarthritis Drugs.改善病情抗风湿药的当前作用。
Arch Bone Jt Surg. 2023;11(1):11-22. doi: 10.22038/ABJS.2021.56530.2807.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验